Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06205966
Status:
RECRUITING
Last Update Posted:
2024-01-16
First Post:
2024-01-02
Brief Title:
A Study to Investigate the Effect of Probiotics L Reuteri ATCC PTA 5289 and L Reuteri DSM 17938 on Symptoms of Viral Upper Respiratory Tract Infections in Children
Sponsor:
Milosevits Gergely
Organization:
Szent Miklós Szolgálat Kft
Study Overview
Official Title:
A Randomized Double Blind Placebo-controlled Study to Investigate the Effect of Probiotics L Reuteri ATCC PTA 5289 and L Reuteri DSM 17938 on Symptoms of Viral Upper Respiratory Tract Infections in Children
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study investigates the effect of Lactobacillus reuteri probiotic strains ATCC PTA 5289 and DSM 17938 on symptoms of viral upper-respiratory tract infections in children
Detailed Description:
Lactobacillus reuteri probiotic strains ATCC PTA 5289 and DSM 17938 have been shown to significantly reduce the number of febrile days and pain severity in upper respiratory tract infections in children aged six months to 5 years The investigators planned study complements this earlier publication by significantly increasing the number of cases and expanding the age range studied including children from 4 to 17 years of age diagnosed with viral upper respiratory-tract infection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None